Medpace (NASDAQ:MEDP) Stock Price Expected to Rise, Mizuho Analyst Says

Medpace (NASDAQ:MEDP) had its price target boosted by analysts at Mizuho from $575.00 to $655.00 in a research note issued to investors on Friday, Marketbeat.com reports. The firm currently has an “outperform” rating on the stock. Mizuho’s price objective points to a potential upside of 8.23% from the company’s current price.

MEDP has been the topic of several other reports. Zacks Research lowered Medpace from a “strong-buy” rating to a “hold” rating in a report on Monday, September 22nd. Rothschild Redb lowered Medpace from a “strong-buy” rating to a “hold” rating in a report on Wednesday, September 3rd. William Blair restated a “market perform” rating on shares of Medpace in a report on Wednesday, July 23rd. TD Cowen restated a “sell” rating and set a $366.00 target price (up from $283.00) on shares of Medpace in a report on Wednesday, July 23rd. Finally, Weiss Ratings restated a “buy (b-)” rating on shares of Medpace in a report on Wednesday, October 8th. Two research analysts have rated the stock with a Buy rating, ten have given a Hold rating and four have assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Reduce” and a consensus price target of $464.00.

Medpace Trading Up 1.4%

MEDP opened at $605.20 on Friday. The stock has a market cap of $17.00 billion, a price-to-earnings ratio of 42.32, a PEG ratio of 3.58 and a beta of 1.40. Medpace has a 1 year low of $250.05 and a 1 year high of $625.00. The stock has a fifty day moving average price of $503.13 and a 200 day moving average price of $392.06.

Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Wednesday, October 22nd. The company reported $3.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.50 by $0.36. Medpace had a return on equity of 91.88% and a net margin of 18.36%.The firm had revenue of $659.90 million during the quarter, compared to analysts’ expectations of $640.49 million. During the same quarter last year, the firm earned $3.01 earnings per share. The business’s revenue for the quarter was up 23.7% on a year-over-year basis. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. As a group, sell-side analysts forecast that Medpace will post 12.29 earnings per share for the current fiscal year.

Insider Transactions at Medpace

In related news, VP Susan E. Burwig sold 10,000 shares of Medpace stock in a transaction dated Wednesday, September 3rd. The stock was sold at an average price of $480.00, for a total transaction of $4,800,000.00. Following the sale, the vice president directly owned 57,500 shares of the company’s stock, valued at $27,600,000. This trade represents a 14.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, General Counsel Stephen P. Ewald sold 3,000 shares of Medpace stock in a transaction that occurred on Monday, July 28th. The shares were sold at an average price of $450.00, for a total value of $1,350,000.00. Following the sale, the general counsel directly owned 10,343 shares in the company, valued at $4,654,350. The trade was a 22.48% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 107,465 shares of company stock valued at $49,720,216 in the last ninety days. 20.30% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Medpace

A number of institutional investors have recently added to or reduced their stakes in MEDP. GAMMA Investing LLC boosted its holdings in Medpace by 37.1% during the first quarter. GAMMA Investing LLC now owns 307 shares of the company’s stock valued at $94,000 after purchasing an additional 83 shares in the last quarter. Bartlett & CO. Wealth Management LLC boosted its holdings in Medpace by 17.5% during the first quarter. Bartlett & CO. Wealth Management LLC now owns 343 shares of the company’s stock valued at $105,000 after purchasing an additional 51 shares in the last quarter. Smith Group Asset Management LLC boosted its holdings in shares of Medpace by 7.3% in the 1st quarter. Smith Group Asset Management LLC now owns 79,694 shares of the company’s stock worth $24,282,000 after acquiring an additional 5,436 shares in the last quarter. Novem Group grew its position in Medpace by 35.3% during the 1st quarter. Novem Group now owns 2,924 shares of the company’s stock worth $891,000 after acquiring an additional 763 shares during the last quarter. Finally, Teacher Retirement System of Texas increased its holdings in Medpace by 2.0% during the 1st quarter. Teacher Retirement System of Texas now owns 7,424 shares of the company’s stock valued at $2,262,000 after purchasing an additional 144 shares in the last quarter. 77.98% of the stock is owned by institutional investors and hedge funds.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.